# A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

> **NCT02286622** · PHASE1 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Deflazacort

## Key facts

- **NCT ID:** NCT02286622
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02286622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02286622, "A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02286622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*